First Gaucher type 3 neurological drug approved - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

First Gaucher type 3 neurological drug approved

  • By

  • Teraya Smith

  • November 18, 2026

  • 2 min

Share

Clinical Scorecard: First treatment for GD3 neurological symptoms approved

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: First Gaucher type 3 neurological drug approved
Key MechanismsMechanisms or clinical associations described in the source article.
Target PopulationPatients or participants described in the source article.
Care SettingFDA-approved for adults and pediatric patients with GD3 weighing at least 15 kg. The supporting trial enrolled patients with stable systemic disease after prior enzyme replacement therapy.

Key Highlights

  • The FDA approved venglustat (Infilbray) as the first treatment authorized for neurological symptoms of GD3.
  • Approval applies to adults and pediatric patients weighing at least 15 kg.
  • In a 52-week trial, venglustat improved a combined neurological assessment compared with enzyme replacement therapy used for nonneurological manifestations.
  • The trial enrolled 43 patients aged 12 years and older who had previously received enzyme replacement therapy and achieved stable systemic disease.
  • Commonly reported adverse effects included gastrointestinal symptoms and mood-related changes; serious psychiatric risks included suicidal ideation and behavior.

Guideline-Based Recommendations

Diagnosis

    Management

    • FDA-approved for adults and pediatric patients with GD3 weighing at least 15 kg.
    • In the 52-week trial, venglustat was taken orally once daily; the comparator was intravenous enzyme replacement therapy every 2 weeks.

    Monitoring & Follow-up

    • Frequently reported adverse effects included gastrointestinal symptoms and mood-related changes.
    • Serious psychiatric risks, including suicidal ideation and behavior, were reported.

    Risks

    • Animal studies identified potential visual clouding risks in younger patients.
    • Animal studies identified adverse effects on fetal development when the drug is taken during pregnancy.

    Patient & Prescribing Data

    FDA-approved for adults and pediatric patients with GD3 weighing at least 15 kg. The supporting trial included patients aged 12 years and older with stable systemic disease after prior enzyme replacement therapy.

    Venglustat is taken orally once daily and was studied for 52 weeks. The FDA announcement did not provide numerical estimates of treatment effects.

    Clinical Best Practices

      Related Resources & Content

        Original Source(s)

        Related Content